Clinical Research Directory
Browse clinical research sites, groups, and studies.
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Sponsor: TORL Biotherapeutics, LLC
Summary
A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer
Official title: CATALINA-4: Phase 1B/2 Study of TORL-1-23 With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Newly Diagnosed Patients With Advanced Stage Ovarian Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-12-10
Completion Date
2028-01
Last Updated
2026-01-07
Healthy Volunteers
No
Interventions
TORL-1-23 and paclitaxel
TORL-1-23 and paclitaxel
TORL-1-23 and carboplatin
TORL-1-23 and carboplatin
TORL-1-23, paclitaxel, and carboplatin
TORL-1-23, paclitaxel, and carboplatin
Locations (1)
UCLA
Los Angeles, California, United States